Gortec - Groupe D'Oncologie Radiothérapie Tête Et Cou

Gortec - Groupe D'Oncologie Radiothérapie Tête Et Cou company information, Employees & Contact Information

Le GORTEC (Groupe d'Oncologie Radiothérapie Tête Et Cou) a été créé en 1999 à partir de cinq centres fondateurs (Clermont-Ferrand, Nancy, Nantes, Tours et Villejuif) dans le but de coordonner la réalisation d'études cliniques et/ou biologiques dans le domaine de la cancérologie cervico-faciale. -Réseau multidisciplinaire d'environ 500 Investigateurs: Chirurgiens, Radiothérapeutes, Oncologues, Radiologues. -Réseau de + de 100 structures de soins en oncologie établis en France, Suisse, Belgique, Tunisie, Allemagne, Espagne -Essais cliniques nationaux et internationaux : Phase III (majoritaires), Phase II & Phase I. -Membre fondateur et moteur de l’Intergroupe ORL labellisée par l’INCa (Institut National du Cancer) depuis 2012 Plus de 150 membres (Médecins référents) Plus de 40 salariés Organisation des réunions scientifiques bi-annuelles (>150 participants)
Looking for a particular Gortec - Groupe D'Oncologie Radiothérapie Tête Et Cou employee's phone or email?

Gortec - Groupe D'oncologie Radiothérapie Tête Et Cou Questions

News

GORTEC Announces New Trial Success for Head and Neck Cancer Treatment - PR Newswire

GORTEC Announces New Trial Success for Head and Neck Cancer Treatment PR Newswire

ASCO 2025 - For the first time in 20 years, a new treatment shows benefit in high-risk head and neck cancers - Gustave Roussy

ASCO 2025 - For the first time in 20 years, a new treatment shows benefit in high-risk head and neck cancers Gustave Roussy

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN - CancerNetwork

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN CancerNetwork

Post-Operative Nivolumab Significantly Improves DFS in Head and Neck Cancer - Targeted Oncology

Post-Operative Nivolumab Significantly Improves DFS in Head and Neck Cancer Targeted Oncology

NIVOPOSTOP Trial Demonstrates DFS Benefit of Adjuvant Nivolumab in High-Risk HNSCC Following Chemoradiotherapy - ASCO Daily News

NIVOPOSTOP Trial Demonstrates DFS Benefit of Adjuvant Nivolumab in High-Risk HNSCC Following Chemoradiotherapy ASCO Daily News

Adjuvant Nivolumab Plus Chemoradiotherapy Meets DFS End Point in Locally Advanced HNSCC - OncLive

Adjuvant Nivolumab Plus Chemoradiotherapy Meets DFS End Point in Locally Advanced HNSCC OncLive

Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial - The Lancet

Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial The Lancet

Nivolumab May Enhance Outcomes with SOC Therapy for Locally Advanced HNSCC - CancerNetwork

Nivolumab May Enhance Outcomes with SOC Therapy for Locally Advanced HNSCC CancerNetwork

Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial - ScienceDirect.com

Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial ScienceDirect.com

Study Finds Durvalumab Plus Carboplatin and Paclitaxel Effective, Tolerable in Frail Patients With Head and Neck Cancer - The ASCO Post

Study Finds Durvalumab Plus Carboplatin and Paclitaxel Effective, Tolerable in Frail Patients With Head and Neck Cancer The ASCO Post

Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial - The Lancet

Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial The Lancet

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, pha - The Lancet

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, pha The Lancet

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial - The Lancet

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial The Lancet

Top Gortec - Groupe D'Oncologie Radiothérapie Tête Et Cou Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant